R
Replimune Group
REPL
10.260
USD
0.26
(2.60%)
مغلق
حجم التداول
20,465
الربح لكل سهم
0
العائد الربحي
0
P/E
-4
حجم السوق
817,807,110
الأخبار
العنوان: Replimune Group
القطاع: Healthcare
الصناعة: Biotechnology
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.